On our screens:Cheap stocks by free cash flow yield
The financials
Teladoc Health, Inc. by the numbers
Teladoc Health, Inc. (TDOC) reported revenue of $614M in Q1 2026 (quarter ended Mar 31, 2026), down 2.5% from the same quarter a year earlier. That came with a gross margin of 68% and net loss of $64M. For the full year FY2025, revenue was $2.53B (−1.5% year on year) and net income −$200M. Its largest product in Jun 2026 was Subscription Access Fees at $474M, 78% of the disclosed total, well ahead of Other at 22%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $614M | $629M | −2.5% |
| Gross profit | $416M | $433M | −3.8% |
| Operating income | −$62M | −$121M | n/a |
| Net income | −$64M | −$93M | n/a |
| Diluted EPS | −$0.36 | −$0.53 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Subscription Access Fees | $474M | 78% |
| Other | $133M | 22% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $606.9M (-1.1%)
Other grew +23% year on yearSubscription Access Fees -9.4% year on year
Segment Latestquarter on quarteryear on year
- Subscription Access Fees$474.2M$474.2MQoQ -2.2%year on year -9.4%-2.2%-9.4%
- Other$132.7M$132.7MQoQ +2.7%year on year +23%+2.7%+23%
Health Information Services
Ranks #13 of 13 by Smart Score